AsiaNet 89309

SCHAFFHAUSEN, Switzerland, May 3, 2021 /PRNewswire=KYODO JBN/ --

- Medical device company Occlutech Holding AG, one of the world's leading

providers of minimally invasive structural heart disease devices, announces the

election of four new members to the board

Occlutech Holding AG ("Occlutech") today announces that Marianne Dicander

Alexandersson, Mette-Marie Harild, Helena Levander, and Michel Lussier have

been elected as members of the Board of Directors of Occlutech. Marianne

Dicander Alexandersson will be nominated as the Chair of the Board of Directors

of Occlutech at the Annual General Meeting on 18 June 2021.

"We are delighted to welcome Marianne, Mette-Marie, Helena, and Michel to

Occlutech's board. Their collective management and industry experience will be

of utmost value to Occlutech as we continue on our exciting journey to drive

the development of world leading products, grow revenue and expand further

geographically," said Sabine Bois, Chief Executive Officer of Occlutech.

Tor Peters and Urs Christen have been re-elected as board members.

Marianne Dicander Alexandersson nominated as chair and elected to the Board of

Directors

Marianne Dicander Alexandersson is a Swedish national and a board professional.

She is currently Chair of Saminvest AB and Sahlgrenska Science Park AB and

board member of Linc AB and Promore Pharma AB. She is also a member of the

advisory council for TLV (The dental and pharmaceutical benefits agency).

Mette-Marie Harild elected to the Board of Directors

Mette-Marie Harild is a Danish national and a medical device industry veteran

who has worked in the pharma/medical industry for more than thirty years. She

has previously held sales and marketing positions at Rhone Poulenc and Janssen

Pharma. She has also served as the Regional Vice President Medtronic A/S in

different regions for 13 years.

Helena Levander elected to the Board of Directors

Helena Levander is a Swedish national and a board professional with 20 years of

experience from the banking and finance sectors as well as from corporate

governance and board work in Sweden and Norway. She is a member of the board of

Stendörren Fastigheter, Rejlers, Concordia Maritime, Lannebo Fonder, and

Factoringgruppen.

Michel Lussier elected to the Board of Directors

Michel Lussier is a Canadian citizen and seasoned Med-tech and Cell Therapy

serial entrepreneur. He serves as Chairman of Celyad Oncology SA, iSTAR Medical

SA, and Gabi Smartcare SA, and has previously spent 15 years at Medtronic Inc

and 10 years at Volcano Corp, where he served as Group President.

About Occlutech

Occlutech is a leading provider of minimally invasive structural heart disease

devices. Occlutech develops, manufactures, and commercializes structural heart

and interatrial shunt products to improve the treatment of patients. Occlutech

has a broad and proven portfolio, with more than 127,000 products sold,

addressing congenital defects, stroke prevention and heart failure. Occlutech

markets and sells its structural heart and interatrial shunt products to

hospitals and clinics in over 80 countries through its direct sales

organization and international network of distribution partners. Occlutech

maintains manufacturing and R&D facilities in Jena, Germany and Istanbul,

Turkey, with a global supply and customer support hub located in Helsingborg,

Sweden.

Contact:

Sabine Bois

CEO Occlutech Group

+49 160 90792130

sabine.bois@occlutech.com

Source: Occlutech Holding AG